HAV

BIOLOGICAL2 trials

Sponsors

Novartis Vaccines, Humacyte, Inc.

Conditions

End Stage Renal DiseaseHemodialysisMeningitis, MeningococcalRenal FailureVascular Access

Phase 2

Safety and Efficacy Assessment of HAV in Patients Needing Vascular Access for Dialysis

CompletedNCT04135417

Humacyte, Inc.End Stage Renal Disease, Hemodialysis, Renal Failure +1

Start: 2019-11-12End: 2022-03-02Updated: 2024-03-19

Phase 3

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants

CompletedNCT00474526

Novartis VaccinesMeningitis, Meningococcal

Start: 2007-03-31End: 2009-11-30Updated: 2014-03-24